Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function

Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function: A Chinese Multicenter Observational Study

Hepatic dysfunction limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis. Established practice guidelines for patients with HCC and impaired liver function are lacking. The treatment allocation in these populations is heterogeneous and remains controversial. This study compared the survival benefits of liver resection (LR) and transarterial chemoembolisation (TACE) in patients with HCC and impaired liver function.

Inclusion Criteria:

• patients with HCC who received conventional LR or TACE

Exclusion Criteria:

• （1） presence of portal vein tumour thrombosis (PVTT), hepatic artery, biliary duct or inferior vena cava invasion
• （2） extrahepatic spread (EHS)
• （3） albumin-bilirubin grade 1 or 3
• （4） Eastern Cooperative Oncology Group Performance Status (ECOG-PS) >1
• （5） tumour number >3
• （6） other tumours or severe cardiac, cerebral, and renal insufficiency
• （7）ascites, hepatic encephalopathy, and jaundice